Guidant continues to prove itself as Boston Scientific’s biggest legal headache. Reuters reports Boston Scientific (BSX) has agreed to pay a $30 million settlement to bring two-year civil lawsuit, and with it allegations that Guidant knowingly sold defective defibrillators used in Medicare patients, to an end. BSX bought Guidant in 2006. Guidant sold the defibrillators, which […]
Materna Medical is at work on a device to help protect the more than 80 percent of women who suffer damage or tearing during childbirth. “The clinical need we’re trying to address is that there’s a tremendous amount of damage that women suffer during childbirth,” Mark Juravic, founder and CEO of the California-based startup, said. That […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]
Is red wine the next breakthrough therapy in the world of drug-eluting stents and balloons? The research looks promising, according to Dr. John Foley, cofounder of Requisite Biomedical. Requisite Biomedical was founded in 2009 to develop intravascular medical device coatings containing a combination of the natural compounds found in red wine – resveratrol and quercetin. […]
A federal judge in California dismissed for the second time a purported class-action lawsuit against Boston Scientific's star-crossed Guidant Corp. pacemaker subsidiary.
The Massachusetts-based maker of new innovative medical devices says the federal government's lawsuit over Guidant defibrillators "should not have a significant financial impact." The Justice Department filed a civil lawsuit on Thursday accusing Guidant, which Boston Scientific acquired in 2006 for $27 billion, of causing healthcare providers to file fraudulent Medicare claims.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Among today's current medical news: Guidant a lawsuit target (again); Merck beefs up its biotech; hospitals and docs upped their lobbying efforts; Baby Boomers' Alzheimer's problems; and just who has an MD?
The Internal Revenue Service wants Boston Scientific to pony up $525.1 million plus interest on back taxes owed by BSX subsidiary Guidant Corp.
The federal government reversed course and decided to intervene in a false claims lawsuit filed against Boston Scientific (NYSE:BSX) subsidiary Guidant Corp., after reviewing the case and conducting more interviews. The U.S. Justice Dept. also wants to move the case to Minnesota, where most of the witnesses live and where “nearly all” of the conduct […]
Boston Scientific's subsidiary Guidant was involved in a six-year dispute over the Ancure device. The plaintiffs claimed the medical device, which was used to treat abdominal aortic aneurysm treatment, caused them severe damage. The Supreme Court declined to hear the appeal.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Boston Scientific Corp. (NYSE:BSX) finally pulled the trigger Thursday, saying it would sell a major business to Stryker Corp. It just wasn't the business Wall Street was expecting it to sell.
Ronald Dollens, the former president and CEO of Guidant Corp., is walking away from his board seat at Abiomed Inc. with one year left on his term. Dollens, who joined the board of the Danvers, Massachusetts-based heart pump maker in 2006, was set to have his board term expire in 2011.
Earlier this week, I e-mailed the head of media relations at Boston Scientific Corp. (NYSE: BSX) on a story about a lawsuit. Not really expecting him to return my message (he didn't and never does), I cced Steve Goodyear, an all round good guy who handles media calls for the company's cardiovascular division in Maple Grove.
A federal judge today rejected a $296 million plea agreement between the U.S. Justice Dept. and Boston Scientific Corp. (NYSE:BSX) subsidiary Guidant Corp. over faulty implantable defibrillators. Earlier this month the Natick, Mass.-based medical devices giant, which paid $26 billion for Guidant in 2006, agreed to plead guilty to a pair of misdemeanor criminal charges for […]
Two Minneapolis Heart Institute doctors are opposing a $296 million plea agreement involving Boston Scientific Corp.’s (NYSE:BSX) Guidant division. Earlier this month, Boston Scientific agreed to settle charges stemming from a four-year investigation into possible criminal violations of the Federal Food, Drug, and Cosmetic Act. Under the terms of the plea, which must still be […]